MDAI vs. NVRO, SGHT, DRTS, TLSI, BWAY, SKIN, AVR, LAKE, INGN, and PROF
Should you be buying Spectral AI stock or one of its competitors? The main competitors of Spectral AI include Nevro (NVRO), Sight Sciences (SGHT), Alpha Tau Medical (DRTS), TriSalus Life Sciences (TLSI), BrainsWay (BWAY), Beauty Health (SKIN), Anteris Technologies Global (AVR), Lakeland Industries (LAKE), Inogen (INGN), and Profound Medical (PROF). These companies are all part of the "medical equipment" industry.
Spectral AI vs. Its Competitors
Nevro (NYSE:NVRO) and Spectral AI (NASDAQ:MDAI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership.
Spectral AI has lower revenue, but higher earnings than Nevro. Spectral AI is trading at a lower price-to-earnings ratio than Nevro, indicating that it is currently the more affordable of the two stocks.
Nevro presently has a consensus price target of $5.36, indicating a potential downside of 8.29%. Spectral AI has a consensus price target of $4.75, indicating a potential upside of 141.12%. Given Spectral AI's stronger consensus rating and higher possible upside, analysts plainly believe Spectral AI is more favorable than Nevro.
Nevro has a net margin of -16.54% compared to Spectral AI's net margin of -40.78%. Spectral AI's return on equity of 0.00% beat Nevro's return on equity.
Nevro received 497 more outperform votes than Spectral AI when rated by MarketBeat users. However, 87.50% of users gave Spectral AI an outperform vote while only 62.07% of users gave Nevro an outperform vote.
Nevro has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Spectral AI has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.
95.5% of Nevro shares are owned by institutional investors. Comparatively, 67.1% of Spectral AI shares are owned by institutional investors. 3.2% of Nevro shares are owned by company insiders. Comparatively, 30.7% of Spectral AI shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Spectral AI had 3 more articles in the media than Nevro. MarketBeat recorded 4 mentions for Spectral AI and 1 mentions for Nevro. Spectral AI's average media sentiment score of 0.89 beat Nevro's score of 0.00 indicating that Spectral AI is being referred to more favorably in the news media.
Summary
Spectral AI beats Nevro on 13 of the 19 factors compared between the two stocks.
Get Spectral AI News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDAI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Spectral AI Competitors List
Related Companies and Tools
This page (NASDAQ:MDAI) was last updated on 6/13/2025 by MarketBeat.com Staff